I agree. On the surface it all looks good for Gates to genetically modify a plant for medicine. Just knowing the man though, he is up to no good. He probably had something important edited out. Maybe edited something sinister in. I just can't trust him.
Brilliant synopsis Charles, it is in the interest of the pharmaceutical industry to try to focus on one, high profit isolate to market with the greatest return on investment (and no undesired conflicting positive effects!), but we need to pivot back towards analysis of fractional compound efficacy and positive co-interactions.
It's at a very early stage but I am looking to see if collaboration with colleagues is possible and it was (despite by cynicism) suggested I get my review peer reviewed and submitted for publication, and try and get some funding to reserve some lab time and conduct further in vivo or clinical trials. I would of course publish in my own name (and yours) and redraft as per feedback. Your framework seems a great place to start!
Awesome. I would like to send you an email of a rough draft of the model I would like to use to see what you think. I have no experience writing that type of thing in the format that is typically used. So do you mind if I send you a rough draft?
Figure out what works in nature first. Wholeheartedly agree! Great write up, thanks! ❤️
I like the "whole leaf of the plant" point.
Over all this is about Gates and his fascist cabal replacing nature in choosing who gets to live and die.
The masters of disorder.
I agree. On the surface it all looks good for Gates to genetically modify a plant for medicine. Just knowing the man though, he is up to no good. He probably had something important edited out. Maybe edited something sinister in. I just can't trust him.
Ok.
Brilliant synopsis Charles, it is in the interest of the pharmaceutical industry to try to focus on one, high profit isolate to market with the greatest return on investment (and no undesired conflicting positive effects!), but we need to pivot back towards analysis of fractional compound efficacy and positive co-interactions.
It's at a very early stage but I am looking to see if collaboration with colleagues is possible and it was (despite by cynicism) suggested I get my review peer reviewed and submitted for publication, and try and get some funding to reserve some lab time and conduct further in vivo or clinical trials. I would of course publish in my own name (and yours) and redraft as per feedback. Your framework seems a great place to start!
Awesome. I would like to send you an email of a rough draft of the model I would like to use to see what you think. I have no experience writing that type of thing in the format that is typically used. So do you mind if I send you a rough draft?
Hi Charles, of course, I would be very interested in that.